 Home > Medical News > Latest Medical News > Janssen's IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of psoriatic arthritis in children

Janssen's IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of psoriatic arthritis in children

 Last Update: 2021-12-11
 Source: Internet
 Author: User

Tags

foliar application

navicular horses treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Janssen, a subsidiary of Johnson & Johnson, announced that it has submitted its IL-12/IL-23 inhibitor Stelara (ustekinumab) supplementary biologics license application (sBLA) to the US FDA for the treatment of 5 Children with juvenile psoriatic arthritis (jPsA) over the age of years

Stelara is a humanized IL-12 and IL-23 antibody.

This application was supported by nine trials for adults with active psoriatic arthritis, adults and children with moderate to severe plaque psoriasis

Reference materials:

[1] Janssen Submits Application Seeking US FDA Approval of Stelara® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express Janssen IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of children with psoriatic arthritis

10-22

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Janssen's IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of psoriatic arthritis in children

Related Articles

Express Janssen IL-12/IL-23 inhibitor submits a new application to the FDA for the treatment of children with psoriatic arthritis